Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
COVID-19: breaking down a global health crisis
Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …
century, with over one-hundred million infections and over two million deaths to date. It is a …
Tofacitinib in patients hospitalized with Covid-19 pneumonia
PO Guimarães, D Quirk, RH Furtado… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis
D Chaudhuri, K Sasaki, A Karkar, S Sharif… - Intensive care …, 2021 - Springer
Purpose Corticosteroids are now recommended for patients with severe COVID-19 including
those with COVID-related ARDS. This has generated renewed interest regarding whether …
those with COVID-related ARDS. This has generated renewed interest regarding whether …
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
KL Chai, E Tomlinson, Z Khosravi… - Cochrane Database …, 2021 - cochranelibrary.com
Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …
from the B cells of an infected host. They are being investigated as a potential therapy for …
Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis—a critical review of its pathogenesis and treatment
JC McMurray, JW May, MW Cunningham… - Frontiers in …, 2020 - frontiersin.org
MIS-C is a newly defined post-viral myocarditis and inflammatory vasculopathy of children
following COVID-19 infection. This review summarizes the literature on diagnosis …
following COVID-19 infection. This review summarizes the literature on diagnosis …
COVID-19: rethinking the lockdown groupthink
AR Joffe - Frontiers in public health, 2021 - frontiersin.org
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused the
Coronavirus Disease 2019 (COVID-19) worldwide pandemic in 2020. In response, most …
Coronavirus Disease 2019 (COVID-19) worldwide pandemic in 2020. In response, most …
A living WHO guideline on drugs to prevent covid-19
Clinical question What is the role of drugs in preventing covid-19? Why does this matter?
There is widespread interest in whether drug interventions can be used for the prevention of …
There is widespread interest in whether drug interventions can be used for the prevention of …